September 25, 2018
Congratulations to Aurinia Pharmaceuticals for completing patient enrollment in the AURORA Phase 3 clinical trial ahead of schedule. The company reported in a press release issued today that due to high patient demand, the target number of patients was surpassed with 358 lupus nephritis (LN) patients enrolled in sites across 27 countries. Lupus nephritis is an inflammation of the kidneys caused by lupus.
The AURORA clinical trial is a global, double-blind, placebo-controlled study to evaluate whether the investigational immunosuppressant voclosporin is effective when added to standard therapy of mycophenolate mofetil (MMF)/CellCept® and low-dose steroids. The primary endpoint for the study is complete renal (kidney) response at one year, after which patients can continue for another two years in an extension study.
Read more for a report of the previous Phase 2 results.
